Make Informed Investment Decisions with Affordable Access to Experts
Discussing BLUE’s new SCD results from ASH 2018 and the sickle cell treatment landscape.Ticker(s): BLUE, GBT
Name: Dr Lewis Hsu - MD/ PhD
Institution: University of Illinois
- Professor of Pediatric Hematology-Oncology and Director of Pediatric Sickle Cell.
- Currently manages 170 patients with sickle cell; Active investigator in multicenter clinical trials of potential therapies for sickle cell sponsored by pharmaceutical companies and by NIH
- Research experience with mouse models and human studies on vascular adhesion of blood cells and inflammation as contributors to sickle vaso-occlusive pain, partial chimeric stem cell transplant for cure, sickle acute chest syndrome, priapism, and nitric oxide therapy
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.